PMID: 2499176Jun 1, 1989Paper

Ifosfamide in advanced carcinoma of the esophagus: a phase II trial with severe toxicity

American Journal of Clinical Oncology
S M AnsellG Falkson

Abstract

Seventeen patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (IFOS) 1.5 mg/m2/day intravenously on days 1-5 every 28 days. Mesna was given concurrently at 20% of the IFOS dose prior to and 4 and 8 h after IFOS for uroprotection. Toxicity in this trial was severe since life-threatening leukopenia occurred in one patient, Grade 3 nausea and vomiting (necessitating termination of treatment) in two patients, and Grade 3 neurotoxicity (cerebellar dysfunction) in two patients. Two patients developed severe infections (Grade 3). Only four patients experienced no toxicity. One patient had a partial response with a response duration of 8 weeks. The median survival of all patients is 10 weeks. It is concluded that IFOS as given in this trial has limited activity in esophagus carcinoma with severe toxicity.

Citations

Jan 1, 1991·Journal of Cancer Research and Clinical Oncology·W P BradeC E Araujo
Nov 20, 2002·European Journal of Gastroenterology & Hepatology·Peter D SiersemaErnst J Kuipers
Nov 20, 2002·European Journal of Gastroenterology & Hepatology·Mark R Anderson, Janusz A Jankowski
Sep 16, 2020·International Journal of Cancer. Journal International Du Cancer·Geoffrey C BuckleKatherine Van Loon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.